Search Results for: Understanding%2BChronic%2B

Budget & Appropriations

Understanding how the federal government funds health programs is key to protecting and advancing research, education, and care for those affected by gastrointestinal (GI) disorders. At IFFGD, we are committed to helping patients, caregivers, and advocates stay informed about the federal budget and appropriations process—how funding decisions are made, where GI health research fits in, […]

Read More »

Centrally Mediated Abdominal Pain Syndrome (CAPS)

People with functional gastrointestinal (GI) disorders can have a variety of symptoms that range from painless diarrhea or constipation to pain associated with diarrhea and/or constipation (usually called irritable bowel syndrome). There is another, less common condition of abdominal pain that is chronic or frequently recurring; it is not associated with changes in bowel pattern […]

Read More »

Comments to FDA November 9, 2000

IFFGD sent the following written comments to the FDA in connection with a November 9, 2000 meeting of the Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory Committee to discuss Lotronex: Recent attention has focused on the new drug, Lotronex, for the treatment of Irritable Bowel Syndrome (IBS) symptoms in women who suffer from IBS-associated […]

Read More »
Skip to content